While activating ARC AgRP/NPY neurons has been shown to be both aversive [136] and rewarding [144] depending on the duration of activation, the positive valence associated with inhibiting ARC AgRP/NPY neurons [136] lends itself well to targeting these neurons for obesity drug development. Here, AGRP is linked to obesity due to melanocortin 4 receptor deficiency.